KEYNOTE-671

NCT03425643 📎

Regimen

Experimental
neoadj pembro+chemo → surgery → adjuvant pembro
Control
neoadj chemo → surgery → placebo

Population

Resectable stage II-IIIB NSCLC

Key finding

EFS HR 0.58 (0.46-0.72); mOS HR 0.72 (0.56-0.93); perioperative pembro significantly improves OS

Source: PMID 37272513

Timeline

  • Enrollment start: 2018-04-24 📎

Guideline citations

  • CSCO NSCLC 2025 ⚠️ OCR source